Capitalize on the High Throughput Screening Shift: Track Thermo Fisher, Agilent, Danaher, Revvity and Tecan as AI-Driven Drug Discovery Reshapes R&D ROI
Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "High Throughput Screening (HTS) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.
The global market for High Throughput Screening (HTS) was estimated at US$42.9 Billion in 2024 and is projected to reach US$45.3 Billion by 2030, growing at a CAGR of 0.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the High Throughput Screening (HTS) market.
Global High Throughput Screening (HTS) Market - Key Trends and Drivers Summarized
High Throughput Screening (HTS) has become a cornerstone methodology in pharmaceutical development and academic research, providing an efficient approach to identifying lead compounds that might evolve into new drugs. Utilizing automation, sophisticated software, and extensive chemical libraries, HTS facilitates the rapid evaluation of numerous compounds against biological targets, mainly proteins, which play critical roles in cellular processes. Introduced in the late 1980s, HTS gained prominence by expediting natural product screenings at major pharmaceutical companies and has expanded its application across various sectors including clinical diagnostics and industrial biotechnology. The ability to quickly sift through millions of compounds and identify those with potential therapeutic effects is invaluable in accelerating the pace of drug discovery. This screening method is versatile, allowing both in vitro and in vivo settings to assess compounds, thereby enabling the discovery of modulators of cellular or physiological endpoints without prior detailed knowledge of the target.
HTS is particularly effective in targeting enzymes due to their significance in disease pathways and as drug targets. Enzymes like kinases, which are involved in many cellular processes and diseases, including cancer and inflammatory disorders, are frequent targets in HTS campaigns. The primary detection methods in these screenings often use fluorescence-based assays, which, despite their high sensitivity, are prone to interference and false positives. To mitigate these issues, HTS assays are designed with specific considerations, such as the inclusion of detergents to avoid aggregates that cause misleading results. Once an assay is developed and validated, HTS can be scaled to a primary screening format using modern automation platforms. This phase integrates robotics, sophisticated liquid handling devices, and sensitive detectors, ensuring that the screenings are conducted efficiently and effectively. The process from hit identification to lead optimization involves scrutinizing compounds for key drug properties such as absorption, distribution, metabolism, excretion (ADME), and toxicity, underscoring HTS`s critical role in the early stages of drug discovery.
The evolution of HTS continues with technological and scientific advancements shaping its methodologies and increasing its impact and efficiency. The integration of artificial intelligence and machine learning enhances data analysis capabilities, allowing for a deeper interpretation of complex datasets. Innovations in assay technology, such as the adoption of microchip-based systems and nanoliter dispensing technologies, are refining the precision and reducing the resource requirements of screenings. The major drivers of growth in HTS include advancements in automation and robotics, the use of microfluidics and nanotechnology, and the increasing demand for personalized medicine, which relies on HTS for identifying unique biomarkers and developing tailored therapies. Moreover, the expansion of biologics and specialty pharmaceuticals, along with supportive regulatory environments and increased funding for drug discovery, are bolstering the adoption of HTS. Collaborations between academia and the pharmaceutical industry are also vital, facilitating knowledge exchange and enhancing the implementation of HTS technologies, particularly critical in responding to global health crises and the public demand for rapid development of effective medications.
Scope of Study:
The report analyzes the High Throughput Screening (HTS) market in terms of units by the following Segments, and Geographic Regions/Countries:
Key Insights:
Why You Should Buy This Report:
Key Questions Answered:
Report Features:
Some of the 41 companies featured in this High Throughput Screening (HTS) market report include:
This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:
Key Attributes:
For more information about this report visit https://www.researchandmarkets.com/r/krzjxq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.